Successfully removed.
Sorry, an error occurred.
|
PublicOptionPlease uploaded a new video
(2 weeks ago)
|
|
| |
|
|
PublicOptionPlease uploaded a new video
(2 weeks ago)
On October 30th 2009,
AMSA students from across the U.S.
gathered urging...
more
On October 30th 2009,
AMSA students from across the U.S.
gathered urging Senators not to trick the
nations patients with a bad biologic
medicines proposal. Filmed and Edited by Brett Vaughn.
less
|
|
| |
|
|
PublicOptionPlease uploaded a new video
(2 weeks ago)
Jay Inslee, July 31, 2009: "A fellow named Eric Limburgh, he's Lim...
more
Jay Inslee, July 31, 2009: "A fellow named Eric Limburgh, he's Limburgh's grandson of fame. He's in Snoquamish Washington who was bedridden due to rheumatoid arthritis til these guys invested about a billion dollars to build a product called "Enbrel."
He's now up walking around, he's a successful artist whose life has been restored because we have laws that allowed investors to put a billion dollar investment that eventually, through luck and incredible creativity, built this drug to save his life.
That's the guy I'm thinking of when I'm voting on this, that does create the appropriate balance of protecting investors' investment and moving forward, and I think that's the right balance."
less
|
|
| |
|
|
PublicOptionPlease uploaded a new video
(2 weeks ago)
Henry Waxman on July 31, 2009 at the Energy and Commerce markup, on Anna...
more
Henry Waxman on July 31, 2009 at the Energy and Commerce markup, on Anna Eshoos biosimilar amendment to H.R.3200: "I know that members of this committee support creation of a biosimilar pathway. I know they believe it will bring competition and reduce the high price of biologics. I endorse that, but I strongly believe that adoption of this amendment exactly the wrong way to achieve increased competition and lower prices nor will it enhance innovation. This amendment enacts a lengthy monopoly period — twelve years — and then allows those periods to be extended indefinitely, the so-called evergreening problem. The evidence is overwhelming that these open-ended monopolies will create huge obstacles to competition. To those who want competition in the biologics market, I refer people to a letter from the CEOs of the 28 major generic drug companies. They say, monopolies with this long an unpredictable period of time — that they will not even enter the biosimilar market because there is no economic incentive for them to do it. To those who want lower cost, look to what the payers are saying and the patients group, a coalition of consumer groups AARP, unions, businesses and state and private payers strongly oppose this amendment because it will rob us of the opportunity to achieve significant cost savings for patients and payers. To those who think this is going to bring innovation look at the report from the federal trade commission which conducted a year-long investigation and concluded that monopolies this long would severely damage both competition and innovation, creating real competition in the drug marketplace is one of the best opportunities we have to control costs. But by passing this amendment, were not only missing a historic opportunity to bend the cost curve. Were guaranteeing higher drug costs for the foreseeable future. I understand a large majority of this committee supports this amendment. I do not. And I will continue to make my case that we need real competition to bring down the costs of our nations drug bill not endless monopolies for the drug industry as members continue to look at this issue. I think they will come to understand that this amendment is not the right way to go."
http://fdlaction....
less
|
|
| |
|
|
PublicOptionPlease uploaded a new video
(1 month ago)
Lee Ehrenberg - POP
Public Option, Please
|
|
